Exagen Inc. Logo

Exagen Inc.

XGN

(1.0)
Stock Price

4,55 USD

-35.11% ROA

-78.9% ROE

-2.89x PER

Market Cap.

47.812.600,00 USD

123.12% DER

0% Yield

-30.56% NPM

Exagen Inc. Stock Analysis

Exagen Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Exagen Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.87x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock maintains a fair debt to equity ratio (77%), indicating a reasonable balance between the money it owes and the ownership it possesses.

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

Negative ROE (-72.17%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-46.81%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-3), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Exagen Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Exagen Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Exagen Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Exagen Inc. Revenue
Year Revenue Growth
2012 926.000
2013 3.055.000 69.69%
2014 11.663.000 73.81%
2015 17.946.000 35.01%
2017 26.807.000 33.05%
2018 32.440.000 17.36%
2019 40.387.000 19.68%
2020 41.975.000 3.78%
2021 48.299.000 13.09%
2022 45.563.000 -6%
2023 53.664.000 15.1%
2023 52.548.000 -2.12%
2024 60.256.000 12.79%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Exagen Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2012 1.055.000
2013 897.000 -17.61%
2014 1.287.000 30.3%
2015 1.367.000 5.85%
2017 1.551.000 11.86%
2018 2.125.000 27.01%
2019 2.176.000 2.34%
2020 3.568.000 39.01%
2021 7.237.000 50.7%
2022 9.876.000 26.72%
2023 5.600.000 -76.36%
2023 4.865.000 -15.11%
2024 4.716.000 -3.16%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Exagen Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 4.855.000
2013 6.564.000 26.04%
2014 13.966.000 53%
2015 15.906.000 12.2%
2017 17.520.000 9.21%
2018 18.275.000 4.13%
2019 27.102.000 32.57%
2020 35.733.000 24.15%
2021 42.841.000 16.59%
2022 49.018.000 12.6%
2023 0 0%
2023 45.928.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Exagen Inc. EBITDA
Year EBITDA Growth
2012 -7.061.000
2013 -7.507.000 5.94%
2014 -11.734.000 36.02%
2015 -8.556.000 -37.14%
2017 -7.172.000 -19.3%
2018 -4.037.000 -77.66%
2019 -8.789.000 54.07%
2020 -14.201.000 38.11%
2021 -24.051.000 40.95%
2022 -39.715.000 39.44%
2023 -20.276.000 -95.87%
2023 -20.669.000 1.9%
2024 -8.632.000 -139.45%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Exagen Inc. Gross Profit
Year Gross Profit Growth
2012 -1.048.000
2013 225.000 565.78%
2014 4.778.000 95.29%
2015 8.413.000 43.21%
2017 12.670.000 33.6%
2018 17.061.000 25.74%
2019 21.579.000 20.94%
2020 25.416.000 15.1%
2021 27.711.000 8.28%
2022 21.349.000 -29.8%
2023 30.824.000 30.74%
2023 29.456.000 -4.64%
2024 36.224.000 18.68%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Exagen Inc. Net Profit
Year Net Profit Growth
2012 -7.324.000
2013 -13.496.000 45.73%
2014 -14.981.000 9.91%
2015 -19.183.000 21.9%
2017 -25.631.000 25.16%
2018 -8.012.000 -219.91%
2019 -12.038.000 33.44%
2020 -16.687.000 27.86%
2021 -26.851.000 37.85%
2022 -47.387.000 43.34%
2023 -21.660.000 -118.78%
2023 -23.689.000 8.57%
2024 -11.864.000 -99.67%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Exagen Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -207
2013 -251 17.93%
2014 -266 5.28%
2015 -305 13.11%
2017 -407 24.88%
2018 -127 -219.69%
2019 -1 0%
2020 -1 100%
2021 -2 0%
2022 -3 50%
2023 -1 -100%
2023 -1 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Exagen Inc. Free Cashflow
Year Free Cashflow Growth
2012 -7.917.000
2013 -7.037.000 -12.51%
2014 -11.422.000 38.39%
2015 -12.707.000 10.11%
2017 -11.535.000 -10.16%
2018 -9.500.000 -21.42%
2019 -10.114.000 6.07%
2020 -14.539.000 30.44%
2021 -22.639.000 35.78%
2022 -36.462.000 37.91%
2023 -15.290.000 -138.47%
2023 -2.910.000 -425.43%
2024 -2.562.000 -13.58%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Exagen Inc. Operating Cashflow
Year Operating Cashflow Growth
2012 -7.477.000
2013 -6.865.000 -8.91%
2014 -10.773.000 36.28%
2015 -11.902.000 9.49%
2017 -10.968.000 -8.52%
2018 -9.301.000 -17.92%
2019 -9.711.000 4.22%
2020 -14.084.000 31.05%
2021 -20.269.000 30.51%
2022 -32.144.000 36.94%
2023 -14.462.000 -122.27%
2023 -2.908.000 -397.32%
2024 -2.426.000 -19.87%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Exagen Inc. Capital Expenditure
Year Capital Expenditure Growth
2012 440.000
2013 172.000 -155.81%
2014 649.000 73.5%
2015 805.000 19.38%
2017 567.000 -41.98%
2018 199.000 -184.92%
2019 403.000 50.62%
2020 455.000 11.43%
2021 2.370.000 80.8%
2022 4.318.000 45.11%
2023 828.000 -421.5%
2023 2.000 -41300%
2024 136.000 98.53%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Exagen Inc. Equity
Year Equity Growth
2012 4.822.000
2013 451.000 -969.18%
2014 -14.056.000 103.21%
2015 -22.184.000 36.64%
2017 -4.638.000 -378.31%
2018 -6.734.000 31.13%
2019 55.659.000 112.1%
2020 41.839.000 -33.03%
2021 84.936.000 50.74%
2022 42.460.000 -100.04%
2023 22.694.000 -87.1%
2023 27.504.000 17.49%
2024 17.585.000 -56.41%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Exagen Inc. Assets
Year Assets Growth
2012 11.266.000
2013 16.451.000 31.52%
2014 17.149.000 4.07%
2015 14.627.000 -17.24%
2017 20.390.000 28.26%
2018 28.887.000 29.41%
2019 88.310.000 67.29%
2020 78.375.000 -12.68%
2021 123.445.000 36.51%
2022 86.221.000 -43.17%
2023 56.944.000 -51.41%
2023 60.928.000 6.54%
2024 49.307.000 -23.57%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Exagen Inc. Liabilities
Year Liabilities Growth
2012 6.444.000
2013 16.000.000 59.73%
2014 31.205.000 48.73%
2015 36.811.000 15.23%
2017 25.028.000 -47.08%
2018 35.621.000 29.74%
2019 32.651.000 -9.1%
2020 36.536.000 10.63%
2021 38.509.000 5.12%
2022 43.761.000 12%
2023 34.250.000 -27.77%
2023 33.424.000 -2.47%
2024 31.722.000 -5.37%

Exagen Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.12
Net Income per Share
-0.95
Price to Earning Ratio
-2.89x
Price To Sales Ratio
0.84x
POCF Ratio
-8.3
PFCF Ratio
-7.52
Price to Book Ratio
2.84
EV to Sales
0.83
EV Over EBITDA
-3.28
EV to Operating CashFlow
-7.84
EV to FreeCashFlow
-7.43
Earnings Yield
-0.35
FreeCashFlow Yield
-0.13
Market Cap
0,05 Bil.
Enterprise Value
0,05 Bil.
Graham Number
4.55
Graham NetNet
0.16

Income Statement Metrics

Net Income per Share
-0.95
Income Quality
0.35
ROE
-0.79
Return On Assets
-0.35
Return On Capital Employed
-0.4
Net Income per EBT
1
EBT Per Ebit
1.1
Ebit per Revenue
-0.28
Effective Tax Rate
0.01

Margins

Sales, General, & Administrative to Revenue
0.97
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.59
Operating Profit Margin
-0.28
Pretax Profit Margin
-0.31
Net Profit Margin
-0.31

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.33
Free CashFlow per Share
-0.35
Capex to Operating CashFlow
-0.05
Capex to Revenue
0.01
Capex to Depreciation
0.17
Return on Invested Capital
-0.4
Return on Tangible Assets
-0.35
Days Sales Outstanding
75.39
Days Payables Outstanding
36.73
Days of Inventory on Hand
45.3
Receivables Turnover
4.84
Payables Turnover
9.94
Inventory Turnover
8.06
Capex per Share
0.02

Balance Sheet

Cash per Share
1,35
Book Value per Share
0,97
Tangible Book Value per Share
0.97
Shareholders Equity per Share
0.97
Interest Debt per Share
1.25
Debt to Equity
1.23
Debt to Assets
0.44
Net Debt to EBITDA
0.04
Current Ratio
4.32
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
39348000
Working Capital
0,03 Bil.
Intangibles to Total Assets
0
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
2487000
Debt to Market Cap
0.45

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Exagen Inc. Dividends
Year Dividends Growth

Exagen Inc. Profile

About Exagen Inc.

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

CEO
Mr. John Aballi
Employee
174
Address
1261 Liberty Way
Vista, 92081

Exagen Inc. Executives & BODs

Exagen Inc. Executives & BODs
# Name Age
1 Mr. John Aballi
Chief Executive Officer, President & Director
70
2 Mr. Kamal Adawi M.S., MBA
Corporate Secretary
70
3 Ryan Douglas
Investors Relations Officer
70
4 Dr. Michael I. Nerenberg M.D.
Chief Medical Officer
70
5 Dr. Tina S. Nova Ph.D.
Executive Chairman of the Board of Directors
70
6 Dr. Andrew L. Concoff FACR, M.D.
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board
70

Exagen Inc. Competitors